DNMT3A, with its methyltransferase activity, is required for tumorigenesis and the progression of various cancer types.[7] Previously, we reported that DNMT3A could catalyze DNA methylation within the promoter regions of the elongator complex subunits to generate chemoresistance in GBC and could also be a therapeutic target to sensitize GBC to gemcitabine therapy,[8] but its role in driving the metastasis of GBC remains unclear. The gene discussed is DNMT3A; the disease is cancer.